HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Solotorovsky, M. Articles by Bugie, E. J. Search for Related Content PubMed Articles by Solotorovsky, M. Articles by Bugie, E. J.

The Effect of Streptothricin on Systemic Infection with Cryptococcus Neoformans in Mice

From the Merck Institute for Therapeutic Research, Rahway, N. J.

Abstract

The recent advances in the chemotherapy of bacterial diseases have not been accompanied by similar progress in the treatment of fungus infections. The widely used antibiotics, penicillin and streptomycin, are not active against fungi in vitro (1, 2). Furthermore, bacitracin, polymyxin, and chloromycetin which are now being studied for possible application in human therapy, have not been reported to possess activity against fungi that are pathogenic for man. On the other hand, streptothricin, hemipyocyanin, clavacin and gliotixin are effective against pathogenic fungi in vitro (3). The pharmacological properties and antibacterial activity of streptothricin have been investigated thoroughly, but it has not been used for human therapy because of its relatively high toxicity in animals (4, 5).

Shortly after Waksman and Woodruff (6) had announced the discovery of streptothricin, Robinson, Smith, and Graessle (2) showed that streptothricin inhibited the growth of Cryptococcus neoformans, Epidermophyton inguinale and Sporotrichum schenkii.